MSK researchers used the genome-editing tool CRISPR to create more potent chimeric antigen receptor (CAR) T cells that don’t tire as easily when attacking cancer cells. The unexpected findings were published in the journal Nature on February 22 and underscore the potential of genome editing to advance immunotherapy for cancer.
Wednesday, February 22, 2017
Researchers from Memorial Sloan Kettering Cancer Center (MSK) today published a seminal review of the rapidly evolving field of precision oncology, which allows doctors to recommend therapies based on a genetic understanding of a person’s cancer. Appearing in the special cancer-focused February 9 issue of Cell, the article — “Implementing Genome-Driven Oncology” — presents a critically self-reflective but solutions-focused perspective on this approach to cancer treatment.
Thursday, February 9, 2017
Today, after a yearlong review and collaborative process, Miami Cancer Institute at Baptist Health South Florida became a full member of the Memorial Sloan Kettering (MSK) Cancer Alliance. Miami Cancer Institute is the third member of the MSK Cancer Alliance, a transformative initiative that aims to improve the quality of care and outcomes for people with cancer in community settings.
Thursday, January 26, 2017
See all press releases